Back to search results

ARTIDIS Nanomechanical Profiling for Pancreatic Cancer

This study is looking at a new test called the NEO-Match® test, which uses the ARTIDIS ART-1 Device. This device measures the tiny mechanical properties of fresh tissue samples from pancreatic lesions. The goal is to see if this test can help predict how well patients with suspected pancreatic cancer will respond to treatment before surgery (neoadjuvant treatment) and if it can accurately identify cancerous lesions. You might be able to join if you are at least 18 years old and need a biopsy for a suspicious pancreatic lesion. Researchers will measure how long you live without the cancer getting worse (Event-Free Survival) and how well the cancer responds to treatment (Pathological Response) for up to 24 months. The current status of this study is unclear.

Study design
This is a single-arm study, meaning all participants receive the same intervention. It aims to enroll 200 participants.
What's involved
If you participate, an additional tissue sample may be collected during your routine biopsy or surgery. Your standard medical care will not be changed or delayed.
Compensation
Not stated in the trial record.
Follow-up
Researchers will follow your Event-Free Survival every 3 months for up to 24 months, and your pathological response will be assessed for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07542041

Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens

Recruiting
NAAges 18+Interventional
ARTIDIS AG
~200 participants
Updated 2026-08-18 on ClinicalTrials.gov
What's tested:ARTIDIS ART-1 Device

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Event-Free Survival (EFS)
Measured over Every 3 months, up to 24 months
+1 more outcome measured

Conditions

Pancreatic Cancer
Pancreatic Neoplasms
Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic Lesions Located at the Body or the Tail

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT07542041

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Moffitt Cancer Center

    Tampa, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Julia Ortega, DMSc, MHS, PA
[email protected]
2404980176
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Ability to understand and willingness to sign a written informed consent form
Clinical indication for fine needle biopsy (FNB) of a suspicious pancreatic lesion accessible for biopsy

Exclusion

Any condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study

What this trial measures

  • Event-Free Survival (EFS)Every 3 months, up to 24 months

    Event-Free Survival (EFS) is defined as the time from initiation of anticancer therapy or study enrollment to the occurrence of an event, including disease progression, discontinuation of treatment for any reason, or death from any cause.

  • Pathological ResponseUp to 24 months (assessed following surgery or biopsy as applicable)

    Pathological response is assessed based on surgical or biopsy specimens and categorized as complete response, partial response, or no response. The analysis evaluates the association between study measurements and pathological response.